Disc Medicine, Inc.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company that completed a business combination with Foresite Capital Acquisition Corp. IV, a healthcare-focused special purpose acquisition company trading under the ticker FSDC and sponsored by Foresite Capital Management, a San Francisco-based life sciences investment firm. Foresite Capital Acquisition Corp. IV conducted its initial public offering in 2021, targeting the biotechnology and life sciences sector. Disc Medicine is focused on developing therapies for serious hematologic diseases and filed an 8-K with the Securities and Exchange Commission on December 29, 2022, reflecting a key milestone in the company's post-combination reporting. Sign up for SpacDesk to access the full filing history, sponsor profile, and deal analytics for this transaction.